IRIS
BUCCISANO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 44.962
EU - Europa 4.394
AS - Asia 2.088
SA - Sud America 48
OC - Oceania 35
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 13
Totale 51.574
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 44.907
DE - Germania 1.211
SG - Singapore 900
IT - Italia 847
CN - Cina 694
UA - Ucraina 613
IE - Irlanda 544
GB - Regno Unito 289
KR - Corea 231
RU - Federazione Russa 215
FR - Francia 178
FI - Finlandia 146
SE - Svezia 142
IN - India 50
PL - Polonia 47
CA - Canada 40
NL - Olanda 37
AU - Australia 31
BE - Belgio 28
IR - Iran 25
JP - Giappone 25
EG - Egitto 24
HK - Hong Kong 23
BR - Brasile 22
AT - Austria 19
VN - Vietnam 19
UZ - Uzbekistan 18
ES - Italia 16
PH - Filippine 14
TR - Turchia 14
MX - Messico 13
TH - Thailandia 12
CZ - Repubblica Ceca 11
PE - Perù 11
CH - Svizzera 10
CL - Cile 10
EU - Europa 9
TW - Taiwan 9
MY - Malesia 8
PK - Pakistan 8
RO - Romania 8
SA - Arabia Saudita 8
ID - Indonesia 7
IQ - Iraq 7
PT - Portogallo 7
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
IL - Israele 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
AR - Argentina 3
BD - Bangladesh 3
NZ - Nuova Zelanda 3
RS - Serbia 3
BH - Bahrain 2
CO - Colombia 2
CR - Costa Rica 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
MA - Marocco 2
NG - Nigeria 2
QA - Qatar 2
SD - Sudan 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
FJ - Figi 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
PS - Palestinian Territory 1
SN - Senegal 1
TN - Tunisia 1
Totale 51.574
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.566
Wilmington 11.985
Houston 9.181
Fairfield 1.533
Ann Arbor 1.086
Chandler 1.086
Ashburn 860
Singapore 797
Seattle 655
Jacksonville 535
Cambridge 531
Dublin 488
Dearborn 384
Medford 352
New York 346
Rome 301
Beijing 253
Santa Clara 228
Lawrence 164
Zhengzhou 151
Boardman 101
San Diego 82
Milan 73
Moscow 73
Menlo Park 60
Mülheim 59
Creede 54
Engelhard 46
Redwood City 46
London 41
Shanghai 41
Nanjing 39
Hefei 34
Center 33
Norwalk 29
Bologna 27
Kraków 27
Munich 27
Brussels 25
Kunming 25
Seoul 25
University Park 24
Falls Church 22
Los Angeles 22
Hangzhou 21
Palo Alto 21
Helsinki 20
Toronto 19
Mountain View 16
Verona 16
Guangzhou 15
Nürnberg 15
Pune 15
Dong Ket 14
Florence 12
Nanchang 12
Bang Bai Mai 11
Brno 11
Chicago 11
Chiswick 11
Lima 11
Naples 11
Saint Petersburg 11
Hackensack 10
Nuremberg 10
Paris 10
San Jose 10
Fuzhou 9
Kilburn 9
Lappeenranta 9
Monte Vista 9
Turin 9
Detroit 8
Frankfurt am Main 8
Groningen 8
Hounslow 8
San Francisco 8
Wuhan 8
Birmingham 7
Council Bluffs 7
Hebei 7
Innsbruck 7
Mumbai 7
Phoenix 7
Redmond 7
Roebling 7
Torre Del Greco 7
Warsaw 7
Washington 7
Alexandria 6
Cairo 6
Jinan 6
Kuala Lumpur 6
Latina 6
Padova 6
Shenyang 6
Siena 6
Bari 5
Brisbane 5
Chengdu 5
Totale 46.063
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 607
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 553
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 477
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 470
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 465
An unusual endoscopic finding in a patient with melena: Multiple gastric ulcers of regular shape 457
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 451
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 450
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 450
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 447
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 446
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 443
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 439
Clinical significance of CD38 expression in chronic lymphocytic leukemia 436
CD7 expression in acute myeloid leukemia 436
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 434
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 431
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 427
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 426
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 425
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 424
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 423
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 423
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 423
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 423
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 421
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 420
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 417
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 417
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 415
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 414
Biological features of acute myeloid leukemia in the elderly 414
Cord blood transplantation in adults with acute myeloid leukaemia. 412
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 409
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 408
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 405
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 404
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 403
AML-M0: a biological and clinical profile 401
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 395
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 395
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 387
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 387
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 387
Biological pattern of AML-M0 versus AML-M1: Response 385
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 383
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 382
Azacitidine for the treatment of patients with acute myeloid leukemia 382
P-glycoprotein expression in de novo acute myeloid leukemia 379
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 379
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 379
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 378
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 378
Blood stem cell processing 378
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 378
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 376
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 376
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 375
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 375
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study 374
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 374
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 374
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 373
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 372
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 369
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 367
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 364
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 362
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 361
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 360
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 359
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 359
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 358
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors 357
Monitoring of minimal residual disease in acute myeloid leukemia 356
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 356
Outcomes of allogeneic stem cell transplantation for secondary therapy-related acute myeloid leukaemia 356
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 354
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 352
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 351
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 348
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. 348
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 347
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 346
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 346
Treatment of low-blast count AML using hypomethylating agents 346
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 345
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 343
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 343
Reversible hyporegenerative anemia during natalizumab treatment 342
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 340
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 339
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 339
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 338
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 335
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 332
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 327
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 325
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 324
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 323
Totale 39.064
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.581
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.581
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010.707 0 0 898 1.156 1.152 1.411 1.247 1.109 1.055 1.076 733 870
2020/20217.478 840 865 745 1.008 769 713 951 711 229 219 328 100
2021/20221.970 66 193 81 67 54 194 131 129 167 177 136 575
2022/20232.972 285 232 219 296 210 575 350 202 334 51 161 57
2023/20241.684 138 48 202 49 139 511 78 112 42 48 46 271
2024/20251.649 174 991 484 0 0 0 0 0 0 0 0 0
Totale 52.235